Follistatin as potential therapeutic target in prostate cancer
- PMID: 23456439
- DOI: 10.1007/s11523-013-0268-7
Follistatin as potential therapeutic target in prostate cancer
Abstract
Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins' inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.
Similar articles
-
The emerging role of follistatin under stresses and its implications in diseases.Gene. 2018 Jan 10;639:111-116. doi: 10.1016/j.gene.2017.10.017. Epub 2017 Oct 8. Gene. 2018. PMID: 29020616 Review.
-
Regulation of ovarian function by the TGF-beta superfamily and follistatin.Reproduction. 2003 Aug;126(2):133-48. doi: 10.1530/rep.0.1260133. Reproduction. 2003. PMID: 12887271 Review.
-
Activins and activin antagonists in the prostate and prostate cancer.Mol Cell Endocrinol. 2012 Aug 15;359(1-2):107-12. doi: 10.1016/j.mce.2011.07.005. Epub 2011 Jul 20. Mol Cell Endocrinol. 2012. PMID: 21787836 Review.
-
Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer.J Clin Endocrinol Metab. 1997 Nov;82(11):3851-8. doi: 10.1210/jcem.82.11.4374. J Clin Endocrinol Metab. 1997. PMID: 9360551
-
Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues.Br J Cancer. 2000 Jan;82(1):112-7. doi: 10.1054/bjoc.1999.0886. Br J Cancer. 2000. PMID: 10638976 Free PMC article.
Cited by
-
Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.EMBO Mol Med. 2020 Apr 7;12(4):e10895. doi: 10.15252/emmm.201910895. Epub 2020 Mar 5. EMBO Mol Med. 2020. PMID: 32134197 Free PMC article.
-
Follistatin is a novel biomarker for lung adenocarcinoma in humans.PLoS One. 2014 Oct 27;9(10):e111398. doi: 10.1371/journal.pone.0111398. eCollection 2014. PLoS One. 2014. PMID: 25347573 Free PMC article.
-
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.Transl Lung Cancer Res. 2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13. Transl Lung Cancer Res. 2023. PMID: 37425411 Free PMC article.
-
Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.Pathol Oncol Res. 2021 Nov 15;27:1610032. doi: 10.3389/pore.2021.1610032. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34867090 Free PMC article.
-
Serum Levels of Follistatin Are Positively Associated With Serum-Free Thyroxine Levels in Patients With Hyperthyroidism or Euthyroidism.Medicine (Baltimore). 2016 Feb;95(5):e2661. doi: 10.1097/MD.0000000000002661. Medicine (Baltimore). 2016. PMID: 26844494 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical